Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Carlsmed, Inc. Common Stock

CARL

Carlsmed Inc is a commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. The company operates as a single operating and reportable segment engaged in the design, manufacture, and marketing of its Aprevo technology platform, which provides customized surgical planning and implants for lumbar and cervical spine fusion procedures, mainly sold to hospitals and ambulatory surgical centers.

Last trade $18.10
Day change +$0.75 (+4.32%)
Day range $16.95 – $18.68
Volume 194,057
Market cap $475M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$475.46M
Price / earnings
—
Price / book
6.28×
Price / sales
6.62×
EV / sales
6.34×
EV / EBITDA
-10.86×

Profitability

Earnings per share
-$1.46
Return on assets
-34.76%
Return on equity
-52.94%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.2×
Current ratio
5.79×
Quick ratio
5.62×
Cash ratio
1.97×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$35.07M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CARL, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025
Revenue$21.55M$18.94M$16.12M$15.17M$13.07M
Cost of revenue$4.89M$4.4M$3.69M$3.56M$3.15M
Gross profit$16.67M$14.54M$12.43M$11.61M$9.93M
Selling, general and administrative$22.99M$19.54M$16.52M$15.66M$14.52M
Research and development$6.38M$6.04M$5.18M$5.26M$4.45M
Total operating expenses$29.37M$25.58M$21.7M$20.93M$18.96M
Operating income-$12.7M-$11.04M-$9.28M-$9.32M-$9.04M
Interest expense-$316K-$313K-$311K-$330K-$380K
Income before taxes-$12.25M-$10.51M-$8.7M-$8.61M-$8.53M
Income taxes$0$0$0$0$0
Net income-$12.25M-$10.51M-$8.7M-$8.61M-$8.53M
Net income attributable to common shareholders-$12.25M-$10.51M-$8.7M-$8.61M-$8.53M
EBITDA-$12.58M-$10.91M-$9.18M-$9.22M-$8.95M
Basic earnings per share-$0.45-$0.39-$0.32-$0.32-$0.40
Diluted earnings per share-$0.45-$0.39-$0.32-$0.32-$0.40

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

DeGen Medical Moves to Dismiss Carlsmed Patent Suit, Vows to Fight Remaining Claims

DeGen Medical filed a motion in U.S. District Court seeking dismissal of key portions of a patent infringement complaint brought by Carlsmed, Inc. DeGen argues that Carlsmed's four asserted method patents claim abstract information processing ineligible for patent protection under Section 101. DeGen emphasizes its human-centered approach to patient-specific spinal implants, contrasting it with Carlsmed's automated, computer-implemented methods.

Zacks Investment Research

Carlsmed, Inc. (CARL) Reports Q3 Loss, Tops Revenue Estimates

Carlsmed, Inc. (CARL) reported a quarterly loss of $0.34 per share, beating consensus estimates of $0.42 loss, with a 19.05% earnings surprise. Revenue reached $21.55 million, surpassing estimates by 10.06% and up 64.8% year-over-year. The stock has gained 30% year-to-date versus the S&P 500's 10.3% gain. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates

Enovis reported Q3 2026 earnings of $0.88 per share, beating consensus estimates of $0.76 by 15.79%, with revenues of $558.73 million slightly exceeding expectations. However, the stock has underperformed the S&P 500 by 20.6% year-to-date. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Carlsmed is expected to report results on November 10 with an anticipated quarterly loss of $0.42 per share.

GlobeNewswire Inc.

Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System

Carlsmed, Inc. announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society's 41st Annual Meeting. The launch follows a limited market evaluation that began in February 2026. The system leverages the company's AI-enabled software platform to deliver personalized spine fusion solutions, with endorsements from surgeons at University of Colorado and Mayo Clinic.

GlobeNewswire Inc.

Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical

Carlsmed, Inc. filed a patent infringement lawsuit against DeGen Medical, Inc. in the U.S. District Court for the District of South Carolina, alleging infringement of eight patents related to AI-enabled personalized spine surgery implants, methods, and systems. Carlsmed is seeking injunctive relief and damages.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 29, 20041-for-200reverse split